Epidermal growth factor receptor expression of non-small cell carcinoma and its relationship with genomic mutation

Korean Journal of Pathology

Volumn 42, Issue 2, 2008, Pages 94-99

  Seok, Sang hee ^a   Kim, Mi Jin ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Carcinoma; Epidermal growth factor; Immunohistochemistry; Mutation; Non Small Cell Lung; Receptor

Indexed keywords

EID: 59849111724     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
2. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000; 18: 106-15.
3. Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology 2002; 16 (9 Suppl 9): 19-24.
4. Massarelli E, Herbst RS. Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol 2006; 33 (Suppl 1): S9-19.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
6. Prudkin L, Wistuba II. Epidermal growth factor receptor abnormalities in lung cancer: pathogenetic and clinical implications. Ann Diagn Pathol 2006; 10: 306-15.
7. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining the HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-7.
8. Fernández Val JF, Losada J, Arregui Murua MA, Sarría R. Cell proliferation, nuclear ploidy, and EGFR and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. Cancer Genet Cytogenet 2002; 138: 69-72.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
10. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
11. Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002; 86: 1449-56.
12. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002; 33: 105-10.
13. Gehring WJ. Homeo boxes in the study of development. Science 1987; 236: 124-52.
14. Lazzaro D, Price M, de Felice M, Di Lauro R. The transcription factor, TTF-1, is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of fetal brain. Development 1990; 113: 1093-104.
15. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996; 9: 445-52.
16. Khoor A, Whitsett JA, Stahlman MT, Olson SJ, Cagle PT. Utility of surfactant protein B precursor and thyroid transcription factor-1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999; 30: 695-700.
17. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: thyroidspecific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev 1996; 10: 60-9.
18. Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor I in thyroid anaplastic carcinoma. Hum Pathol 2000; 31: 1139-45.
19. Cohen S, Ushiro H, Stoscheck C, Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982; 257: 1523-31.
20. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
21. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29 (1 Suppl 4): 3-14.
22. Suzuki S, Kobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: an immunohistochemical and fluorescence in situ hybridization study. Cancer 2005; 103: 1265-73.
23. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small-cell lung cancer: a meta-analysis. Thorax 2006; 61: 140-5.
24. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-807.
25. Ahn JH, Kim SW, Hong SM, et al. Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci 2004; 19: 529-35.
26. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227-32.
27. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
28. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-62.
29. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
30. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathological characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thoracic Oncol 2006; 1: 231-9.
31. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
32. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes. J Clin Oncol 2005; 23: 6838-45.
33. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55.
34. Lee J, Choi J, Jang SJ. Clinicopathologic analysis of epidermal growth factor receptor status in non-small cell lung cancer: protein expression, gene amplification and survival analysis. Korean J Pathol 2007; 41: 387-92.